BioNTech SE
BNTX
$93.66
$0.320.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.50% | -228.35% | -115.41% | 49.54% | -27.92% |
| Total Depreciation and Amortization | 209.06% | -248.79% | 197.47% | 7.77% | 8.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -530.58% | 1,852.50% | 121.26% | -398.40% | 107.15% |
| Change in Net Operating Assets | 116.90% | 64.13% | 201.41% | -76.06% | -286.08% |
| Cash from Operations | 41.19% | 172.95% | 229.95% | -90.51% | -138.51% |
| Capital Expenditure | -26.67% | -3.63% | 47.56% | 67.75% | 18.97% |
| Sale of Property, Plant, and Equipment | 248.94% | -6.39% | 928.02% | 163.59% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.80% | -575.37% | -1,263.36% | 73.95% | 159.29% |
| Cash from Investing | 131.83% | -590.61% | -592.47% | 71.87% | 152.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.04% | -160.27% | -45.57% | 41.92% | -76.92% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 308.62% | -113.92% | -54.80% | 38.76% | -71.51% |
| Foreign Exchange rate Adjustments | 76.97% | -88.76% | -894.06% | 393.96% | -329.52% |
| Miscellaneous Cash Flow Adjustments | 194.18% | 201.28% | -97.28% | -82.82% | 80.13% |
| Net Change in Cash | 483.66% | -2,022.83% | 75.03% | -93.63% | 115.26% |